| WANBURY  | 
The Current P/S Ratio of WANBURY  is 1.46.
                
| Share Price | ₹263.2 | Oct 31,2025 | 
| Market Cap | ₹918.4 Cr | |
| Sales-TTM | ₹629.8 Cr | TTM-Consolidated Results | 
| Price/Sales | 1.46x | Calculated as Market Cap/Sales | 
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PS (Price/Sales) ratio of WANBURY
                    P/S = 
                    Market Capitalization  
                    /
                    Sales
                    
                    or, using per-share numbers:
                    
                    P/S = Stock Price / Sales Per Share
                
                Current Market Cap [ ₹918.4 Cr] as on Oct 31,2025                
                                    (/) Sales [ ₹629.8 Cr] based on TTM-Consolidated Results
                                    
                
                (=) P/S Ratio [ 1.46x ]
            
Thus, for WANBURY , the investors are currently willing to pay '1.46 times sales' to own 1 share of the company.
PS Multiples are one of the most widely used valuation multiple in the industry.
P/S ratios can be a reliable benchmark to compare companies with negative earnings or book value.
You may also explore Price to Earnings ratio or Price to Book ratio of WANBURY !
The chart below summarizes the trend in P/S Ratio of WANBURY over the last five years.
Historical PS (Price/Sales) ratio chart of WANBURY
PS Ratio Performance Analysis for WANBURY
- WANBURY 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 0.68x.
- WANBURY 's operated at median p/e ratio of 0.54x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, WANBURY 's p/e ratio peaked in Mar2025 at 1.28x.
- WANBURY 's p/e ratio hit its five-year low in Mar2023 of 0.24x.
How does WANBURY 's P/S Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Sales (Cr) | PS Ratio | Market Cap (Cr) | 
|---|---|---|---|
| WANBURY | 629.8 | 1.46 | 918.4 | 
| SUN PHARMACEUTICAL INDUSTRIES LTD | 53,777.1 | 7.54 | 405,452.0 | 
| DIVIS LABORATORIES LTD | 9,652.0 | 18.55 | 179,089.0 | 
| CIPLA LTD | 28,349.6 | 4.28 | 121,299.0 | 
| TORRENT PHARMACEUTICALS LTD | 11,835.0 | 10.18 | 120,456.0 | 
| DR REDDYS LABORATORIES LTD | 34,310.0 | 2.91 | 99,965.9 | 
| MANKIND PHARMA LTD | 12,956.2 | 7.59 | 98,333.5 | 
| ZYDUS LIFESCIENCES LTD | 23,607.7 | 4.15 | 98,057.5 | 
| LUPIN LTD | 23,375.9 | 3.84 | 89,722.4 | 
| AUROBINDO PHARMA LTD | 32,024.8 | 2.07 | 66,133.0 | 
| ABBOTT INDIA LTD | 6,589.9 | 9.35 | 61,629.9 | 
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PS Analysis vs WANBURY 's P/S Ratio
| Top 10 Industry Peers | PS Ratio | 
|---|---|
| Min industry PS | 1.46x | 
| Max industry PS | 18.55x | 
| Median industry PS | 4.28x | 
| Average industry PS | 6.54x | 
You may also like the below Video Courses
 
                                     
                                     
                                    